Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 2, 2014, Pages 316-323

  Han, Zheng Lan ^a   Fang, Quan ^a   Wang, Zi Long ^a   Li, Xu Hui ^a   Li, Ning ^a   Chang, Xue Mei ^a   Pan, Jia Xin ^a   Tang, Hong Zhu ^a   Wang, Rui ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 1 RECEPTOR AGONIST; MOUSE VD HEMOPRESSIN(ALPHA); NALOXONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; AVERSION; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CONDITIONING; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG TOLERANCE; FOOD INTAKE; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PLACE AVERSION; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REWARD; TAIL FLICK TEST;

EID: 84893098805     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.209866     Document Type: Article

References (31)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, and Monory K, et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870-879.
2. Blais PA, Côté J, Morin J, Larouche A, Gendron G, Fortier A, Regoli D, Neugebauer W, and Gobeil F, Jr (2005) Hypotensive effects of hemopressin and bradykinin in rabbits, rats and mice. A comparative study. Peptides 26:1317-1322.
3. Blankman JL and Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65:849-871.
4. Bomar MG and Galande AK (2013) Modulation of the cannabinoid receptors by hemopressin peptides. Life Sci 92:520-524.
5. Bushlin I, Rozenfeld R, and Devi LA (2010) Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10:80-86.
6. Dale CS, Pagano RdeL, Rioli V, Hyslop S, Giorgi R, and Ferro ES (2005) Antinociceptive action of hemopressin in experimental hyperalgesia. Peptides 26: 431-436.
7. De Vry J, Jentzsch KR, Kuhl E, and Eckel G (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12.
8. Dodd GT, Mancini G, Lutz B, and Luckman SM (2010) The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J Neurosci 30:7369-7376.
9. Dodd GT, Worth AA, Hodkinson DJ, Srivastava RK, Lutz B, Williams SR, and Luckman SM (2013) Central functional response to the novel peptide cannabinoid, hemopressin. Neuropharmacology 71:27-36.
10. Fairbanks CA (2003) Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev 55:1007-1041.
11. 2 receptors mediated antinociception in mice. Neuropharmacology 62:855-864.
12. Gardner EL (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81:263-284.
13. Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, Scarlata S, Fricker LD, and Devi LA (2009) Novel endogenous peptide agonists of cannabinoid receptors. FASEB J 23:3020-3029.
14. Guindon J and Beaulieu P (2009) The role of the endogenous cannabinoid system in peripheral analgesia. Curr Mol Pharmacol 2:134-139.
15. Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, Luchessi AD, Castro LM, Giorgi R, and Rioli V, et al. (2007) Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 104:20588-20593.
16. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, and Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567-1577.
17. Hylden JL and Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313-316.
18. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, and Malan TP, Jr (2006) CB2 cannabinoid receptor mediation of antinociception. Pain 122:36-42.
19. Lichtman AH and Martin BR (1991) Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258:517-523.
20. Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95:153-164.
21. Mechoulam R and Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21-47.
22. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
23. Panlilio LV, Justinova Z, and Goldberg SR (2010) Animal models of cannabinoid reward. Br J Pharmacol 160:499-510.
24. Parolaro D, Rubino T, Viganò D, Massi P, Guidali C, and Realini N (2010) Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 11:393-405.
25. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
26. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
27. Reche I, Fuentes JA, and Ruiz-Gayo M (1996) A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol- induced analgesia in mice. Eur J Pharmacol 301:75-81.
28. Richardson JD (2000) Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1:2-14.
29. Rioli V, Gozzo FC, Heimann AS, Linardi A, Krieger JE, Shida CS, Almeida PC, Hyslop S, Eberlin MN, and Ferro ES (2003) Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme. J Biol Chem 278:8547-8555.
30. Rosow CEMJ, Miller JM, Pelikan EW, and Cochin J (1980) Opiates and thermoregulation in mice. I. Agonists. J Pharmacol Exp Ther 213:273-283.
31. Welch SP, Huffman JW, and Lowe J (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286:1301-1308.